



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/543, 33/548, 33/555, 33/564, 33/80	A1	(11) International Publication Number: WO 97/32213 (43) International Publication Date: 4 September 1997 (04.09.97)
<p>(21) International Application Number: PCT/US97/02889</p> <p>(22) International Filing Date: 27 February 1997 (27.02.97)</p> <p>(30) Priority Data: 08/609,705 1 March 1996 (01.03.96) US</p> <p>(71) Applicant (for all designated States except US): MAJESCO BIOLOGICALS, INC. [US/US]; 244 Fernwood Avenue, Edison, NJ 08837 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GREENSPAN, Howard [US/US]; 23 Spring Hill Road, Annandale, NJ 08801 (US). COLANDUONI, John [US/US]; 248 West Lehigh Street, Bethlehem, PA 18018 (US).</p> <p>(74) Agents: BROOK, Mitchell, P. et al.; Baker & McKenzie, 12th floor, 101 West Broadway, San Diego, CA 92101 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: BLOOD TESTING KIT</p> <p>(57) Abstract</p> <p>An improved blood testing kit and method of testing blood is provided. The improved kit may be provided in two or more forms including a strip from whereby a membrane (30) and an absorbent pad (31) are attached to a backing sheet in a juxtaposed relationship with one another. A portion of one side of the membrane (30) is treated with antibodies that will react with the antigens for A type, B type and RH+ blood. Another embodiment includes the placement of a membrane over an absorbent pad (31) within a housing. A hole or aperture (32) is disposed in the pad (31) underneath a portion of the membrane (30). Discrete portions of the membrane are treated with antibodies specific to the A type, B type and RH+ blood antigens. If the antibodies are disposed on the underside of the membrane, a membrane having a pore size of approximately 20 microns is utilized. If the antibodies are disposed on the top or upper surface of the membrane (30), a membrane having a smaller pore size of 3-8 microns is utilized.</p> <div data-bbox="1068 1201 1339 1396" style="text-align: right;"> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

BLOOD TESTING KIT

FIELD OF THE INVENTION

5 This invention relates generally to apparatus for testing blood including tests for blood type or viral infections, such as HIV. More specifically, this invention relates to the use of membranes in blood testing apparatuses.

BACKGROUND OF THE INVENTION

10 Blood testing is normally performed in a laboratory setting requiring several steps for each type of test to be performed. While the present invention is directed toward two basic type of blood tests, blood type testing and testing for viral infections,
15 other applications will be apparent to those skilled in the art. Blood typing is performed by detecting the type of antigen that is contained within a person's blood. Specifically, a person with A type blood has the A antigen in their blood cells; people with B type blood have the B antigen in their blood cells; people with AB
20 type blood have both the A antigen and the B antigen in their blood cells; and people with O type blood have neither the A nor the B antigen.

 Most prior art methods of typing blood rely upon an agglutination process whereby the red cells agglutinate in the
25 presence of a specific antigen type antibody. Specific antigen type antibodies exist for all blood types except type O. For example, A type red blood cells will react with a specific antigen type antibody which results in a clumping or aggregation of the A type blood cells and the A type antigen antibodies. Thus, if A
30 type blood is exposed to the specific antigen antibody for A type blood, the result is a clumping of A type red blood cells and the antibody. The visual appearance of the clumping is a positive indication that the blood is A type. Similarly, clumping will occur when B type red blood cells are exposed to B type antibodies.
35 In the case of AB type blood, the blood sample must be exposed to

both A type antibodies as well as B type antibodies. The clumping reaction for both types of antibodies is a positive indication for AB type blood. Finally, in the case of O type blood no clumping will occur when exposed to A type or B type antibodies. Similar agglutination methods are used for RH factor determination. A schematic diagram illustrating the agglutination method is presented in Figure 1.

Another process utilizes size exclusion chromatography. In this method, a mixture of blood and antibody is placed in a test tube on top of a layer of gel. The tube is then placed in a centrifuge. If the sample contains red cells with the specific antigen on their surface, the cells and antibody will clump together and will not be able to be centrifuged through the gel. If the sample does not contain red cells with the specific antigen on their surface, the cells will easily be centrifuged through the gel. Therefore, red blood cells that are centrifuged through the gel is a negative reaction and a band of red cells disposed on the top of the gel after centrifuging is a positive reaction. The size exclusion chromatography method is illustrated in Figure 2.

Until now, chromatography was the only method of size exclusion blood typing or blood testing. Membranes, if used at all, were merely used for an indication of a positive reaction at the surface of the membrane. However, with recent advances in membrane technology, it would be particularly useful to utilize membranes in a size exclusion blood testing method.

Specifically, the antigen or reactant could be disposed on an underside or an opposing side of a membrane. Blood then could be forced to proceed through the membrane before reacting with the antigen or other reactant. The remaining components of the blood could be thereafter absorbed or washed away leaving the blood cell-reactant aggregate disposed against the underside of the membrane. Because membranes are clear, the result could be an easy-to-read indicator such as a line or a dot. Further, separate antigens or reactants could be placed at discrete locations on the membrane to provide multiple indication in one test kit. For example, both A type and B type as well as RH positive antibodies could be placed on discrete areas of the membrane so that one test apparatus could provide positive indications for A, B, AB, O, RH

positive and RH negative blood. Such a system would not require the use of a centrifuge or excessive handling by a technician.

SUMMARY OF THE INVENTION

5 The invention is an improved apparatus for testing blood, such as testing blood type and testing for viral infections. One apparatus made in accordance with the present invention includes a backing sheet for accommodating a membrane on one surface section of the backing sheet and an absorbent pad on a second surface
10 section of the backing sheet. The membrane and absorbent pad are in a juxtaposed relationship with one another. On the underside of the membrane, antibodies corresponding to A, B and RH positive blood cells are arranged in discrete areas of the membrane. One preferred method is to place a horizontal "stripe" of antibody
15 corresponding to each blood type in a parallel relationship. The backing sheet, absorbent pad and membrane are then cut into strips. The purpose of the absorbent pad is to absorb liquid as it flows through the membrane. When the blood cells react with an antibody or other reagent, the aggregation is too large to pass through the
20 membrane and a red stripe appears where the antibody or reagent was placed on the membrane.

A second and related embodiment features a membrane mounted onto the top of an absorbent pad. The absorbent pad includes a hole or aperture disposed in the middle of the pad. The membrane/
25 pad combination are then accommodated in a housing which includes an opening or access hole disposed above the portion of the membrane covering the hole or opening in the absorbent pad. The appropriate antibodies or reagents are previously placed in discrete areas of the membrane portion which is disposed over the
30 hole in the pad. Blood is then applied directly to the top of the membrane and subsequently washed away with a buffer solution. Blood cells which react with the antibodies or reagents form an aggregation or bright red area after the remaining components of the blood are washed away with the buffer solution.

35 A membrane having approximately a 20 micron pore size is preferable for use with both blood testing apparatuses described above. Red blood cells are approximately seven to eight microns in diameter. Thus, unreacted red blood cells will pass through the 20 micron membrane. However, once the red blood cells react with

an antibody or other suitable reagent to produce an aggregate, the aggregate cannot pass through the 20 micron pore size. As the remaining components of the blood are washed away with a buffer solution, the aggregate combination is left behind to provide a bright red indicator on the under surface of the membrane. Because the membranes are transparent, a clear visual indication is provided.

In contrast, it may be desirable to allow the blood and reagents to aggregate on the surface of the membrane. In such a situation, a membrane with a smaller pore size, such as 3-6 microns is provided so that the blood and reagents will bind to the surface of the membrane.

It is therefore an object of the present invention to provide an improved apparatus for testing blood.

Yet another object of the present invention is to provide an improved blood-type testing kit.

Still another object of the present invention is to provide an improved apparatus for testing viral infections in human blood.

Another object of the present invention is to provide an improved method for testing blood.

Other objects and advantages of the present invention will become apparent upon reading the following detailed description of the drawings and appended claims, and upon reference to the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is illustrated more or less diagrammatically in the accompanying drawing wherein:

Figure 1 is a schematic diagram illustrating a positive reaction between an antibody and a red blood cell with the specific antigen and a negative reaction between an antibody and a red cell without the specific antigen;

Figure 2 is an illustration of the prior art method of using size exclusion chromatography in testing blood;

Figure 3 is a top plan view of a plastic backing sheet used in one blood testing apparatus made in accordance with the present invention;

Figure 4 is a top plan view of the plastic backing sheet shown in Figure 3 with a membrane applied to a lower surface section thereof;

Figure 5 is an illustration of the backing sheet and membrane shown in Figure 4 further with an absorbent pad attached to the backing sheet in a juxtaposed relationship with respect to the membrane;

Figure 6 is an illustration of the embodiment shown in Figure 5, cut into strips and illustrating the reactions for A-, A+, B-, B+, AB-, AB+, O- and O+ blood types;

Figure 7 is a side view illustrating the attachment of a membrane to an absorbent pad for a second embodiment made in accordance with the present invention;

Figure 8 is a top plan view of the absorbent pad first shown in Figure 7;

Figure 9 is a side sectional view illustrating the membrane and absorbent pad shown in Figure 7 contained within a housing; and

Figure 10 is an illustration of eight blood testing apparatus shown in Figure 9 indicating A-, A+, B-, B+, AB-, AB+, O- and O+ blood types.

It should be understood that the drawings are not necessarily to scale and that the embodiments are sometimes illustrated by graphic symbols, phantom lines, diagrammatic representations and fragmentary views. In certain instances, details which are not necessary for an understanding of the present invention or which render other details difficult to perceive may have been omitted. It should be understood, of course, that the invention is not necessarily limited to the particular embodiments illustrated herein.

DETAILED DESCRIPTION OF THE DRAWINGS

Like reference numerals will be used to refer to like or similar parts from Figure to Figure in the following description of the drawings.

Turning to Figure 1, an antibody 11, a red blood cell 12 and a red blood cell 13 are shown at the left. The red blood cell 12 includes an antigen which will react positively with the antibody 11 which will result in an aggregation, shown generally at 14. The aggregation 14 is a positive reaction or a positive indication that

the red blood cell 12 is of the blood type specific to the antibody 11. In contrast, the antibody 11 will not react with the red blood cell 13 because the red blood cell 13 lacks the specific antigen. The combination of the antibody 11 and the red blood cell 13 is a negative reaction or lack of clumping, indicated generally at 15. The aggregation or agglutination shown at 14 is useful in size exclusion chromatography as shown in Figure 2.

A size exclusion chromatography method is illustrated in Figure 2. A test tube 16 is filled with a gel 17. A mix type of red blood cells and a specific antibody are placed on top of the gel 17 at the area indicated generally at 18. The test tube 16 is then placed in a centrifuge (not shown). If no reaction takes place between the antibody and the red blood cells, the red blood cells shown at 20 will centrifuge downward toward the lower end of the test tube below the gel, indicated generally at 19. The test tube shown in the middle of Figure 2 indicates a negative reaction, because the red blood cells 20 were able to pass through the gel 17 during the centrifuge process. In contrast, the red blood cells shown in the test tube 16 at the far right of Figure 2 reacted with the antibody and formed an aggregation 21 which was not able to pass through the gel 17 during the centrifuge process. As a result, the red blood cells in combination with the antibodies are shown at 21, disposed on top of the gel 17. The aggregation was unable to pass through the gel and therefore the area disposed at the bottom 19 of the test tube 16 remains clear.

The size exclusion chromatography process shown in Figure 2 is inconvenient for several reasons. Specifically, only one antibody or reagent may be used at a time. Thus, several tests are required to determine blood type which requires the use of several test tubes. Further, a centrifuge is required.

One embodiment of the present invention is illustrated in Figures 3 through 6. Figure 3 is an illustration of a backing sheet 22 which, as shown in Figure 4, accommodates a membrane 23. The dotted lines 24, 25 which pass through the membrane 23 are intended to indicate the placement of antibodies on either the top side or underside of the membrane 23. Figure 5 illustrates the placement of an absorbent pad 26 on top of the backing sheet 22 and in a juxtaposed relationship with respect to the membrane 23. As fluid passes through the membrane 23, it is absorbed into the pad

26. The apparatus 27 shown in Figure 5 can then be cut into strips 28a through 28h as shown in Figure 6.

Turning now to Figure 6, the membrane 23 has been coated with three specific antibodies -- the specific antibody for A type blood, the specific antibody for B type blood and the specific antibody for RH+ blood. As illustrated to the left of the strip 28a, the A type, B type and RH+ antibodies are coated on the membrane in spaced apart parallel stripes. The use of the three different antibodies enables the test strips 28 to indicate eight different results. Specifically, the test strip 28a gives a positive indication for A- blood. The test strip 28b is a positive indication for A+ blood. The test strip 28c gives a positive indication for B- blood; the test strip 28d gives a positive indication for B+ blood. Similarly, the test strips 28e and 28f gives positive results for AB- and AB+ blood respectively. Finally, the test strips 28g, 28h give positive results for O- and O+ blood respectively.

The test strips 28a through 28h as shown in Figure 6 can be used as follows: the blood samples are collected in a standard method with any type of anticoagulant to stop clotting. Approximately five microliters of blood is then added to a 12mm by 75mm test tube along with approximately 95 microliters of buffer containing 1% BSA, 50mM sodium phosphate ph 7.4, with 0.1 percent sodium azide. The strip 28 is then added to the tube with the membrane 23 on the bottom and the solution is allowed to migrate up the strip 28 to the absorbent pad 26. The results can then be observed within one to four minutes.

A second embodiment of the present invention is illustrated in Figure 7. Specifically, a membrane 30 is placed on top of an absorbent pad 31 as shown in Figure 7. As shown in Figures 7 and 8, the pad 31 includes a hole or aperture 32 over which the membrane 30 is placed. As shown in Figure 9, the membrane 30 and pad 31 are contained within an outer housing that includes a top 33 and bottom 34. Use of the apparatus 35 is further illustrated in Figure 10. Each membrane 30 includes three different antibodies, placed in discrete and separate positions, as illustrated by the kit 35f which indicates AB+ blood. The kit 35a indicates a positive reading for A- blood; the kit 35b indicates a positive reading for A+ blood. Similarly, the kits 35c, 35d

indicate positive readings for B- and B+ blood respectively. The kits 35e, 35f indicate positive readings for AB- and AB+ blood respectively. Finally, the kits 35g, 35h provide positive readings for O- and O+ blood respectively.

5 The kit 35 is used as follows. Fifty microliters of blood is placed on the top of the membrane 30. The blood is then allowed to sit for sixty seconds. The membrane is then washed with 1mL of the above-described buffer solution to remove the unreacted blood cells. The results as shown in Figure 10 are then interpreted.
10 A red dot on the left hand side denotes A type antigen. A red dot on the right hand side denotes B type antigen. A red dot in the upper center portion of the membrane 30 indicates RH+.

15 The preferred membrane is comprised of mixed esters of cellulose. The preferred pore size is approximately 20 microns. However, the pore size may vary. One preferred membrane is sold under the HIFLOW-SX™ which is sold in strips that are twelve inches wide, having a thickness of 115-155 microns. The top 33 and bottom 34 may be manufactured from plastic, such as PVC. The backing sheet 22 may also be manufactured from plastic.

20 Instead of utilizing a 20 micron membrane, a membrane having a smaller pore size, such as three microns may be utilized. If a 3 micron membrane is utilized, the antibodies should be applied to the top or front surface of the membrane. The reaction or aggregation will take place on the membrane's surface as opposed
25 to the underside of the membrane as illustrated above. Finally, a 20 micron membrane may be utilized alone, without being fabricated into a strip form, such as the strips 28 as shown in Figure 6 or the kits 35 as shown in Figure 10. Specifically, ten microliters of blood may be mixed with twenty microliters of
30 antibody solution with fifty microliters of buffer. This mixture may then be pipetted directly onto the membrane. A bright red spot will appear in positive samples as the agglutinated antibody red cell complex will not be able to pass through the twenty micron pore membrane. In a negative sample, the red cells pass through
35 the membrane and no clumping is observed.

 The use of membrane in accordance with the present invention will be useful for other types of testing, other than blood-type testing. Specifically, the invention and methods of using the invention will be useful for the detection of viral infections,

such as HIV. Further, the present invention may be utilized to detect any type of a blood condition that may be otherwise detected by agglutination or aggregation.

5 Although only a limited number of embodiments of the present invention has been illustrated and described, it will at once be apparent to those skilled in the art that variations may be made within the spirit and scope of the invention. Accordingly, it is intended that the scope of the invention be limited solely by the scope of the hereafter appended claims and not by any specific
10 wording in the foregoing description.

WHAT IS CLAIMED IS:

1. An apparatus for testing blood, the apparatus comprising:
a backing sheet including a front surface thereof, the front
surface of the backing sheet including a first section and a
section;

a membrane sheet being attached to the first section of the
backing sheet, a first limited portion of the membrane sheet being
coated with an antibody;

an absorbent pad being attached to the section of the backing
sheet, the membrane sheet and absorbent pad being in juxtaposed
relationship with one another.

2. The apparatus of claim 1,
wherein the membrane has a pore size ranging from about 3
microns to about 25 microns.

3. The apparatus of claim 2,
wherein the pore size about 20 microns.

4. The apparatus of claim 2,
wherein the pore size about 3 microns.

5. The apparatus of claim 1,
wherein the antibody is selected from the group consisting of
antibody for A antigen, antibody for B antigen and antibody for RH
positive antigen.

6. The apparatus of claim 5,
wherein the membrane sheet includes a second limited portion
that does not overlap said first limited portion, the second
limited portion being coated with an antibody that is different
than the antibody that the first limited portion is covered with.

7. The apparatus of claim 6,
wherein the membrane sheet includes third limited portion that
does not overlap said first and second limited portions, the second
limited portion being coated with an antibody that is different
than the antibodies that the first and second limited portions are
covered with.

8. An apparatus for testing blood, the apparatus comprising:
a backing sheet including a front surface thereof, the front
surface of the backing sheet including a first section and a
section;

5 a membrane sheet being attached to the first section of the
backing sheet, the membrane including a pore size of approximately
20 microns, a first limited portion of the membrane sheet being
coated with an antibody selected from the group consisting of
antibody for A antigen, antibody for B antigen, and antibody for
10 RH positive antigen, a second limited portion that does not overlap
said first limited portion, the second limited portion being coated
with an antibody that is different than the antibody that the first
limited portion is covered with, a third limited portion that does
not overlap said first and second limited portions, the second
15 limited portion being coated with an antibody that is different
than the antibodies that the first and second limited portions are
covered with;

an absorbent pad being attached to the section of the backing
sheet, the membrane sheet and absorbent pad being in juxtaposed
20 relationship with one another.

9. An apparatus for testing blood, the apparatus comprising:
a bottom receptacle including an upper opening defined by an
upper rim for accommodating a membrane sheet and an absorbent pad;

25 the membrane sheet overlying the absorbent pad, a first
limited portion of the membrane sheet being coated with an antibody
selected from the group consisting of antibody for A antigen,
antibody for B antigen and antibody for RH positive antigen;

the absorbent pad including an opening, the first limited
30 portion of the membrane sheet being suspended over an area defined
by the opening of the absorbent pad.

10. The apparatus of claim 9,
wherein the membrane has a pore size ranging from about 3
35 microns to about 25 microns.

11. The apparatus of claim 10,
wherein the pore size about 20 microns.

12. The apparatus of claim 10,
wherein the pore size about 3 microns.

13. The apparatus of claim 9,
5 wherein the membrane sheet includes a second limited portion
disposed within the opening of the absorbent pad, the second
limited portion does not overlap said first limited portion, the
second limited portion being coated with an antibody that is
different than the antibody that the first limited portion is
10 covered with.

14. The apparatus of claim 12,
wherein the membrane sheet includes third limited portion
disposed within the opening of the absorbent pad, the third limited
15 portion does not overlap said first and second limited portions,
the third limited portion being coated with an antibody that is
different than the antibodies that the first and second limited
portions are covered with.

20 15. A method for testing blood comprising the following
steps:

collecting a blood sample;
adding an anticoagulant to the blood sample;
adding BSA to the blood sample;

25 placing a blood testing apparatus in the blood sample, the
blood testing apparatus including

a backing sheet including a front surface thereof,
the front surface of the backing sheet including a first
section and a section, a membrane sheet being attached
30 to the first section of the backing sheet, a first
limited portion of the membrane sheet being coated with
an antibody selected from the group consisting of
antibody for A antigen, antibody for B antigen and
antibody for RH positive antigen, an absorbent pad being
35 attached to the section of the backing sheet, the
membrane sheet and absorbent pad being in juxtaposed
relationship with one another;

waiting for blood to adhere to the first limited portion of
the membrane.

16. A method for testing blood comprising the following steps:

collecting a blood sample;

adding an anticoagulant to the blood sample;

5 adding BSA to the blood sample;

placing the blood sample into a blood testing apparatus, the blood testing apparatus including

10 a bottom receptacle including an upper opening defined by an upper rim for accommodating a membrane sheet and an absorbent pad, the membrane sheet overlying the absorbent pad, a first limited portion of the membrane sheet being coated with an antibody selected from the group consisting of antibody for A antigen, antibody for B antigen and antibody for RH positive antigen, the
15 absorbent pad including an opening, the first limited portion of the membrane sheet being disposed within the opening of the absorbent pad;

waiting for blood to adhere to the first limited portion of the membrane.

20 17. A method for testing blood comprising the following steps:

collecting a blood sample;

adding an anticoagulant to the blood sample;

25 adding BSA to the blood sample;

adding an antibody to the blood sample;

placing a portion of the blood sample onto a membrane;

waiting for blood and antibody to adhere to the membrane or pass through the membrane.

1/2




Fig. 1




Fig. 2
(PRIOR ART)




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Fig. 10




Fig. 7




Fig. 8





Fig. 9



INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US97/02889
A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : G01N 33/543, 33/548, 33/555, 33/564, 33/80

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---- Y	US 4,943,522 A (EISINGER et al.) 24 July 1990, see entire document.	1-16 ----- 17
X ---- Y	US 4,851,210 A (HEWETT) 25 July 1989, see entire document, especially columns 6-8 and Figures 3a-5.	1, 4-7, 9, 12-16 ----- 17
X	WO 88/08534 A1 (UNILEVER PLC) 03 November 1988, see entire document.	1-4
Y	US 5,213,963 A (UTHEMANN) 25 May 1993, see entire document, especially columns 1-2.	17
Y	US 4,552,839 A (GOULD et al.) 12 November 1985, see entire document, especially columns 1, 2, 3, 4 and 8.	17

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 09 MAY 1997	Date of mailing of the international search report 21 JUL 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer JAMES L. GRUN, PH.D. Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/02889

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y ---- A	US 4,379,847 A (FRUITSTONE et al.) 12 April 1983, see entire document, especially columns 1-2.	17 ----- 15-16
A	US 4,459,361 A (GEFTER) 10 July 1984, see entire document.	17

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/02889

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

435/7.25, 287.2, 287.3, 287.7, 287.8, 287.9, 288.3, 288.7; 422/56, 57, 58; 436/520, 530, 169

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

435/2, 7.21, 7.25, 287.2, 287.3, 287.7, 287.8, 287.9, 288.3, 288.7, 967, 970, 971, 975; 422/56, 57, 58, 68.1;
436/506, 518, 520, 528, 530, 164, 169, 810